Board and Committees

Mr Tsai is a former Chairman of Deloitte China and has more than 35 years of experience in planning and managing audits for Hong Kong based operations of multi-national groups, as well as local and overseas listed clients in a wide range of industries. As a Fellow of the Hong Kong Institute of Certified Public Accountants (the “HKICPA”), the Association of Chartered Certified Accountants and the Institute of Chartered Accountants of England and Wales (the “ICAEW”), Mr Tsai is actively involved in the development of the CPA profession and also contributes his efforts in various government, community and social services organisations.

Mr Tsai is a Past President of the HKICPA, a Council Member of the ICAEW, a Member of the Hospital Authority, the Chairman of the Hospital Governing Committee of the Queen Mary Hospital and Tsan Yuk Hospital, the Chairman of the Supplementary Medical Professions Council of the Health Bureau, a Member of the Audit and Risk Committee of the Mandatory Provident Fund Schemes Authority, an Advisor of The Ombudsman, Hong Kong, a Member of the Registration Committee of the Chinese Gold and Silver Exchange, a Member of Para Athletes Career and Education Programme Committee of the China Hong Kong Paralympic Committee and a Member of the Independent Commission on Remuneration for Members of the Executive Council and the Legislature, and Officials under the Political Appointment System of the HKSAR Government.

Moreover, Mr Tsai is a Member of the University Grants Committee, an Honorary Court Member and the Chairman of the Student Residence Board of the Hong Kong Baptist University, the Deputy Chairman of the Alumni Committee of The Hong Kong Baptist University Foundation, a Trustee of the Staff Superannuation Scheme of The Chinese University of Hong Kong and a Member of the Institutional Advancement and Outreach Committee of the University Council of The Hong Kong University of Science and Technology.

Mr Tsai is also an Advisory Board Member of the Hong Kong Red Cross.

Professor Liang is a Specialist in Haematology and Haematological Oncology. He is currently Head of Department of Medicine, Director of Comprehensive Oncology Centre and Assistant Medical Superintendent of Hong Kong Sanatorium and Hospital. He is also Emeritus Professor of The University of Hong Kong (HKU) and Honorary Professor of both HKU and The Chinese University of Hong Kong.

Professor Liang was a member of the Hospital Authority Board. Furthermore, he was the Ex-Dean of Li Ka Shing Faculty of Medicine, HKU, and the Past President of the Hong Kong Academy of Medicine.

Professor Liang was one of the founders of Hong Kong Blood Cancer Foundation and Hong Kong Marrow Match Foundation. The latter was responsible for establishing the first all Chinese Unrelated Marrow Donor Registry, serving Chinese patients in need of bone marrow transplantation in Hong Kong, Macau, Taiwan and Mainland China, as well as Chinese patients around the world.

Dr Lo joined Hong Kong Genome Institute (HKGI) as the Chief Executive Officer in March 2021.  As the CEO, Dr Lo leads HKGI in formulating its strategic direction and development plan.  He also provides leadership to the team in launching the Hong Kong Genome Project, the city’s first-ever large-scale whole genome sequencing initiative.  With the aspiration to benefit the wider community, Dr Lo drives the team to be the change agent in fostering clinical application of genomic medicine and its long-term development in Hong Kong.

Dr Lo is a seasoned professional in public health and administrative medicine, bringing with him a wealth of knowledge in public healthcare system, service provision and relevant policies.  He also has a strong blend of experience in corporate affairs, strategic planning, talent development, research and so on.  Prior to his current role, Dr Lo had served in the Hospital Authority (HA) for over 20 years during which he had held various senior management positions, including Director of Strategy and Planning in the HA Head Office and Cluster Chief Executive of the New Territories East Cluster.

Currently, Dr Lo is a member of the Steering Committee on Health and Medical Innovation Development under the Health Bureau of the HKSAR Government. He also held a number of senior positions both locally and overseas previously. These included being the Head of Research Office in the former Food and Health Bureau (currently the Health Bureau) of the HKSAR Government, and the Director of Purchasing (Specialist Care Services) with the Cardiff Health Authority of the National Health Service in the United Kingdom.

Professionally, Dr Lo is a practitioner in Public Health and Administrative Medicine.  He had served as a Part I and II examiner of the Faculty of Public Health, and a censor and examiner of the Royal Australasian College of Medical Administrators.

Professor Chan is currently the Associate Dean (Translation and Entrepreneurship) and Chairperson of Chemical Pathology at the Faculty of Medicine of the Chinese University of Hong Kong (CUHK). He is also the Chief of Service for Chemical Pathology at the Prince of Wales Hospital.  He graduated from the Medical School of the University of Hong Kong and received training in internal medicine and gastroenterology. In 2001, he started his PhD training at CUHK.

Professor Chan’s main research interest focuses on the development of new diagnostic approaches based on circulating DNA analysis. He is a co-inventor of over 120 inventions in the fields of noninvasive prenatal testing and cancer detection, with an impressive 1,500 patents granted worldwide. He was named the “Top 20 Translational Researchers of 2020” by the world-renowned scientific journal Nature Biotechnology in 2021.  Professor Chan has led a prospective trial involving over 20,000 subjects to investigate the use of liquid biopsy for the screening of early nasopharyngeal carcinoma (NPC).  This work was published in the top journal the New England Journal of Medicine and was selected as that journal’s ten most notable articles in 2017. In recognition of his contributions, Professor Chan received the esteemed “Annual Achievement Award” from the Chinese Society of Clinical Oncology in 2018 and he has been endowed with the “Tony Mok Shu Kam Professorship in Medicine” by CUHK in 2024.

Mr Chan is the Chief Executive Officer and co-founder of 9GAG, a global multi-platform community for viral content and interests. Founded in 2008, 9GAG’s mission is to make the world happier.

9GAG has a global audience of 200 million, including 56 million followers on Instagram, 42 million followers on Facebook, and 16 million followers on Twitter.

Mr Chan graduated from The University of Hong Kong with a degree in Law.

Ms Cheung is the Senior Partner of KPMG Hong Kong. She was the Past President of the Hong Kong Institute of Certified Public Accountants. She currently serves as member of various public service committees, including the Standing Commission on Civil Service Salaries and Conditions of Service, and the Standing Committee on Company Law Reform, the Consumer Council and the Transport Advisory Committee. Apart from being a member of the Advisory Committee, the Honorary Advisory Panel and the Inspection Committee of the Accounting and Financial Reporting Council, she is the Director of Hong Kong Cyberport Management Company Limited and Insurance Authority.

Ms Cheung had served as Member of the Air Transport Licensing Authority, the Financial Reporting Review Panel, the Independent Commission on Remuneration for Members of the District Councils of the HKSAR, the Non-local Higher and Professional Education Appeal Board, the Occupational Retirement Schemes Appeal Board, the Securities and Futures Appeals Tribunal and the Standing Committee on Disciplined Services Salaries and Conditions of the Service.

Professor Herbert Chia is an Independent Non-executive Director of Hong Kong Exchanges and Clearing Limited, a listed public company in Hong Kong. He has around 15 years of practical experience in big data strategy and application with unique insights into the future trends of e-commerce. He joined Alibaba in 2010 and served as the Vice President of Alibaba (China) Co., Ltd. and the President of Data Committee. During his tenure with Alibaba, the data team of Alibaba was awarded “China Excellent IT Team” in the “Excellent Chinese CIO” selection in 2014. Professor Chia was rated as “China Top 10 Most Influential Big Data Entrepreneurs” by the State Information Center of China in 2017 and garnered Outstanding Achievement Award in 2021 AI Golden Goose Awards of China. He is also a former Venture Partner of Sequoia Capital China and a former member of the Board of Directors of Hong Kong Science and Technology Parks Corporation.

Professor Chia has been making significant contributions in helping to bring China’s big data industry to a new level and has actively promoted Hong Kong to become the big data pilot city in The Greater Bay Area and The Belt and Road. In Hong Kong, he serves as a co-opted member of the Information Technology Services Committee of the Hospital Authority of Hong Kong Special Administrative Region, a non-official member of the Education Commission and the Digital Economy Development Committee and Vice President of GBA International Information Technology Association.

Professor Chia is the Adjunct Associate Professor of The University of Hong Kong (Institute for China Business) and Professor of Practice of the Hong Kong Management Association. He is also the author of various best-selling books including The Big Data and The Nature of Big Data. He holds an Executive Master of Business Administration (EMBA) Degree from Tsinghua University and an EMBA Degree from the Institut Européen d’Administration des Affaires (INSEAD).

Professor Lau is the Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at the University of Hong Kong (HKU).

He graduated with MBChB from the University of Dundee in 1985 and in 1992, he joined HKU’s medical faculty as Lecturer in Medicine and successfully rose through the ranks to his current position as Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology.

Professor Lau has been a major player in rheumatology in Hong Kong and beyond. Locally, he was President of the Hong Kong Society of Rheumatology (1997 – 2001) and Founding Chairman of the Hong Kong Arthritis & Rheumatism Foundation (2001). He was also the President of the Hong Kong Academy of Medicine (2016 – 2020), a statutory body for medical and dental specialist training in Hong Kong which is also a key advisory body to the HKSAR Government on health-related policies. In addition, Professor Lau sits on numerous strategic committees/working groups of the Health Bureau, Hospital Authority and Department of Health.

Regionally, Professor Lau was President of the Asia Pacific League of Rheumatology Associations (APLAR) between 2006 and 2008 and co-founder of the Asia Pacific Lupus Collaboration – a multi-national, multi-centre research collaboration.

Beyond the Asia Pacific region, he was a Member of the Outcome Measures in Rheumatology (1999 – 2002), European Alliance of Associations for Rheumatology (EULAR) Task Force on Rheumatoid Arthritis Treatment Recommendations (2019) and EULAR Scientific Committee (2019-2023). He was selected as an Honorary Member of EULAR in 2022, a member of the Academia Europaea in 2023, and conferred the degree of Doctor of Science honoris causa by the University of Glasgow in 2024. Professor Lau is Honorary Fellow of the American College of Physicians; the Academy of Medicine, Singapore; Singapore College of Physicians; Royal College of Physicians of Thailand; Academy of Medicine of Malaysia; the Royal College of Physicians of Ireland; and the Hong Kong Academy of Medicine.

Dr Leung is the founder, Chairman and Chief Executive Officer of SinoMab BioScience Limited. Currently, he is also a Member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited.

Dr Leung has over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. He was the first scientist who successfully developed humanised anti-CD22 antibody and introduced the concept of “Functional Humanisation”. Dr Leung currently also serves as an Adjunct Professor at The Hong Kong University of Science and Technology. He held positions as the Executive Director of a leading US antibody-drug conjugate company as well as the Managing Director of The Hong Kong Institute of Biotechnology Limited.

Dr Leung obtained his BSc and MPhil in biochemistry, as well as EMBA from CUHK. He earned his DPhil in molecular biology from the University of Oxford in the UK in May 1989. He was also a postdoctoral fellow at Yale University in the US from July 1989 to June 1991.

Dr Liu is the Head of Baker McKenzie’s Asia Pacific Intellectual Property (IP) and Technology Group. She advises clients on matters relating to the creation, exploitation and protection of IP rights. She is also responsible for the local IP Group’s China and Hong Kong patent prosecution matters. Previously, Dr Liu was the Head of the Firm’s Asia Pacific Healthcare and Life Sciences Industry Group for three years, leading a team of legal experts in this field across multiple practices in the region.

Dr Liu is ranked as a leading lawyer in her field by top legal directories such as Chambers Asia Pacific for the Life Sciences category and IAM Patent. She has been complimented by clients that she possesses “a superb ability to understand the most complex technologies” and was noted for “advis[ing] in a way that is very commercial and strategic.”

Professor Lo is the Vice-Chancellor and President and Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong (CUHK) and the President of the Hong Kong Academy of Sciences. His research interests focus on the biology and diagnostic applications of cell-free nucleic acids in plasma. In particular, he discovered the presence of cell-free fetal DNA in maternal plasma in 1997 and has since then been pioneering non-invasive prenatal diagnosis using this technology. This technology has been adopted globally and has created a paradigm in prenatal medicine. He has also made many innovations using circulating nucleic acids for cancer detection, including the screening of early stage nasopharyngeal cancer.

In recognition of his research, Professor Lo has been elected as Member of the Chinese Academy of Sciences (CAS), Founding Member of the Hong Kong Academy of Sciences, Fellow of the Royal Society and Foreign Associate of the US National Academy of Sciences. Professor Lo has won numerous awards, including the 2014 King Faisal International Prize in Medicine, the 2016 Future Science Prize in Life Science, the 2019 Fudan-Zhongzhi Science Award, the 2021 Breakthrough Prize in Life Sciences, the 2021 Royal Medal, the 2021 ESHG Mendel Award, the 2022 ISPD Pioneer Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, the 2023 inaugural Tengchong Science Prize and the 2024 Jiménez Díaz Lecture Award.

Mr Pang is a registered social worker dedicated to protecting and advocating patients’ rights. He works as Community Organizer in Society for Community Organization. He has been a Member of the Hospital Authority (HA) Review Steering Committee, a Member of the Patient Focus Group of the Hospital Accreditation Project under HA, a Member of the Working Group on Implementation of Modified Referral System for Physiotherapy Services under the Physiotherapists Board, and a Member of the Committee on Promoting Acceptance of People Living with HIV/AIDS under Hong Kong Advisory Council on AIDS.

Mr Pang is now a Member of the Working Group on Oral Health and Dental Care, and a Member of the Working Group on Electronic Health Record Partnership of the Steering Committee on eHealth.

Mr Wong is currently a practising barrister, an arbitrator of Shanghai Arbitration Commission and a qualified dispute resolver of Academy of Experts (London).  He had graduated from The University of Hong Kong before he was awarded with a Government Legal Scholarship to further his studies and professional training in the United Kingdom.  Mr Wong obtained his Master in Laws (Intellectual Property, Marine Business and Insurance, Civil Litigation) from the London School of Economics and Political Science, as well as the qualification of a practising solicitor from the Supreme Court of England and Wales.

Upon his return to Hong Kong, Mr Wong joined the then Attorney General’s Chambers as a Crown Counsel, and assumed various posts including Assistant Director of Public Prosecutions, Head of China Law and Basic Law, Deputy Solicitor-General, Secretary-General of the Law Reform Commission and Privacy Commissioner.  Since 2020, he has been a Barrister-at-Law in private practice, focusing on International Public Law, Data and Information Law, Innovation, Communications and Technology, Civil and Commercial Law, Company, Trust and Economic Criminal Law by providing professional legal advice and court advocacy services to local, mainland and overseas public, private and multi-national organisations, as well as small and medium-sized enterprises.

Current community services Mr Wong undertakes include Member of the HKSAR Election Committee (Legal), Director of China Law Society, Expert Member of Shenzhen Municipal Law Compliance Commission, Expert Member of FinTech Committee of Asian Financial Cooperation Association, Adjunct Law Professor of Beijing Normal University, Chairman of the Independent Vetting Committee of Hong Kong Institute of Big Data, Executive Committee Member of Hong Kong International Law Association and Honorary Adviser of Hong Kong Institute of Bankers.

Mr Wong’s publications include two works on Hong Kong Privacy Law (one published in English and the other in Chinese), and chapters on data-related issues in international medical and health journals.

Professor Wong holds the Regius Chair in Pharmacy at Aston University in England, a position established by the late Queen Elizabeth II to mark her 90th birthday.  He joined the University of Hong Kong in 2011 and was the Head of the Department of Pharmacology and Pharmacy.  His expertise lies in using healthcare big data research to investigate the safety and optimal use of medications for treating various conditions, specifically neurological and psychological conditions.  His spin-off companies from UCL and the University of Hong Kong have developed several marketed paediatric medicines in Europe and Hong Kong, which are widely used by children.  In recognition of his contributions to medicines for children, he was awarded an honorary fellowship from the Royal College of Paediatrics and Child Health.

Professor Wong has advised the Departments of Health in England and Hong Kong, the World Health Organization, the European Medicines Agency, and the pharmaceutical industry on various issues related to medication safety.  He has approximately 700 peer-reviewed papers published in prominent journals and was a highly cited researcher in 2024.

During the pandemic, Professor Wong was commissioned by the Hong Kong SAR Government to monitor the safety of COVID-19 vaccines on behalf of the Department of Health.  In 2022, the Chief Executive of the Hong Kong SAR Government awarded him a Commendation for Community Service for his contributions to the fight against the pandemic.

Dr Wong is currently the Director of Quality and Safety of the Hospital Authority (HA). Under his leadership, the Quality and Safety Division oversees the quality standards, patient safety, clinical incident management, patient relations management, healthcare technology assessment, disasters response and infection control for the public hospitals under HA.

Dr Wong is a specialist in haematology & haematological oncology, and has also attained fellowship qualification in pathology. Prior to his current appointment, he has been the Chief Manager (Cluster Performance) in Head Office, Chief Manager of Kowloon West Cluster, Deputy Hospital Chief Executive of the North Lantau Hospital and Deputy Hospital Chief Executive (Operation) of Princess Margaret Hospital.

Professor Wong is the Dean of Science and Chair Professor of Life Science at The Hong Kong University of Science and Technology (HKUST).  He also serves as the Director of the Molecular Neuroscience Center, and as an Associate Director of the Biotechnology Research Institute and the Center for Aging Science at HKUST.

Professor Wong obtained his PhD in Pharmacology from the University of Cambridge and conducted postdoctoral training at the University of California San Francisco.  Since joining HKUST, his research has been focused on the delineation of the mechanisms of cell signalling, particularly those involving drug receptors.  Professor Wong has integrated his scientific endeavours into drug discovery and development in collaboration with pharmaceutical companies.

As an accomplished researcher, he has published over 220 scientific articles and received a number of awards, including the Croucher Senior Research Fellowship and the Medal of Honor.  Over the years, Professor Wong had served as a member of the Medical Council of Hong Kong, the Consumer Council of Hong Kong, and the Research Grants Council of Hong Kong (Biology and Medicine Panel).

He is currently serving on the Sir Edward Youde Memorial Fund Council and the Advisory Board of Hong Kong Life Sciences Society. Professor Wong is also a consultant for The Hong Kong Science and Technology Parks Corporation, multinational companies, and local secondary schools to promote biotechnology.

Professor Yip has been the Head of the Department of Health Technology and Informatics at The Hong Kong Polytechnic University since 2016. He is also the Chair Professor of Diagnostic Science and Molecular Genetics. He is a medical laboratory technologist and a human geneticist by training. He obtained his PhD in human genetics from University College London in 1997.

After working for 10 years in the Pathology Department of United Christian Hospital in Hong Kong, Professor Yip joined the then Hong Kong Polytechnic in 1990 and has since been dedicated to the medical laboratory science education. His research interests focus on the genetics and genomics of complex diseases such as shortsightedness. He is also interested in molecular diagnostics and keen to transfer developed novel technologies to relevant healthcare and testing industries for widespread frontline use.

Professor Yip is one of the founders and council members of the Hong Kong Society for Molecular Diagnostic Sciences.

Professor Yiu is currently a professor and the Deputy Head at the Department of Computer Science of The University of Hong Kong (HKU). He is also the Director of the Department’s FinTech and Blockchain Laboratory and the Deputy Executive Director of HKU–Standard Chartered Hong Kong FinTech Academy. He was selected three times by Clarivate Analytics as one of the Highly Cited Researchers in the world in 2016, 2017 and 2019, and one of the top 1% researchers in HKU for 11 consecutive years (2011 – 2021).

Professor Yiu’s research areas include bioinformatics, cybersecurity, privacy technology, and FinTech. In the areas of bioinformatics, he served as the conference chair in Hong Kong for RECOMB 2017, one of the flagship conferences in the field and as the area programme chair for other prestigious bioinformatics conferences such as ISMB. In addition to academic research, Professor Yiu has been a consultant to various companies in the areas of cybersecurity and data privacy.

Dr Lee is the Under Secretary for Health. Her major duties include assisting the Secretary for Health in the setting of public health policy objectives and priorities, handling Legislative Council business and strengthening the working relationship with Legislative Council, as well as engaging and liaising with all stakeholders to explain and solicit support for government policies and decisions.

Dr Lee was the Commissioner for Primary Healthcare of the Health Bureau. She joined the executive team of the Hospital Authority in 2008 and was promoted to Director of Strategy and Planning in 2016. Dr Lee has served on various professional bodies including as Council Member for the Hong Kong College of Community Medicine and the Hong Kong College of Anaesthesiologists.

Dr Lee holds a medical degree and a master’s degree in public health from The University of Hong Kong as well as a number of professional qualifications. She is trained as an anaesthesiologist and a practitioner in administrative medicine.

Mr Hui is currently the Deputy Secretary for Health, responsible for formulation of policies on medical services and healthcare system and infrastructure, including matters relating to public health, prevention of communicable diseases, operation and development of public and private hospitals, healthcare financing (including Voluntary Health Insurance Scheme), research and health data as well as genomic medicine development.

Prior to this appointment, Mr Hui was the Deputy Representative of the Hong Kong Economic and Trade Office in Brussels from 2016 to 2020, and the Deputy Secretary for Financial Services and the Treasury (Financial Services) from 2020 to 2023.

Dr Li is a specialist in Public Health Medicine and currently the Deputy Director of Health. She oversees areas related to health services and administration including elderly health, family and student health, specialised services, administration and policy, finance, health administration and planning, and health information and technology.